Artículo

Challenges in Launching a Precision Pediatric Oncology Program in Argentina

Paladino, María Mercedes ; Pinto, Nicolás ; Verón, David ; Morosini, Fabiana ; Garcia Rivello, Hernan Jorge ; Alves Da Quinta, Daniela Belén Icon; Ganiewich, Daiana ; Varela, Mariana ; Diez, Blanca ; de Dávila, María Teresa ; Villarroel, Milena ; Rodrigues, Karla Emília de Sá ; Villanueva, Gabriela ; Solorzano, Daniel ; Casanovas, Alejandra ; Rotondaro, Cecilia Icon; Arrossi, Silvina Icon; Chantada, Guillermo Luis Icon; Llera, Andrea Sabina Icon

Otros responsables

Fecha

04/2026

Editorial

Wiley-liss, div John Wiley & Sons Inc.

Revista

Pediatric Blood & Cancer

Título del libro

Nombre del evento

Fecha del evento

Institución organizadora

ISSN

1545-5009

eISSN

ISBN

Idioma

Inglés

Tipo del evento

Clasificación temática

Resumen

Background/Objectives: Advances in pediatric cancer care have underscored the importance of tumor sequencing for diagnosis and treatment selection. However, access to genomic diagnostics in Latin America remains limited. The COPPA Project, an initiative based in Argentina, was conceived to assess the feasibility of delivering clinically useful genomic sequencing for childhood cancers at no cost while maximizing the clinical value of genomic data through multidisciplinary molecular tumor boards (MTBs). Design/Methods: Project planning involved securing funding, establishing a sequencing facility, selecting and optimizing an NGS panel, training technical staff in sequencing and interpretation, addressing sample transportation logistics, recruiting oncologists from multiple institutions, and promoting the establishment and participation in a virtual MTB. Tumors underwent sequencing using the Illumina Cancer Childhood Panel. Results were reported and discussed with the treating physicians and during MTB meetings. A survey was administered to MTB participants to assess perceived barriers and facilitators related to the project. Results: A total of 38 tumors were analyzed, 24 of which were sequenced in-house. Genomic findings were considered to have clinical utility in 67% of cases. Barriers such as a low demand for studies and oncologists’ lack of time for MTBs were identified. Survey responses highlighted the educational value of the MTBs, with all respondents reporting increased knowledge of precision medicine and greater motivation to adopt genomic testing in clinical practice.Conclusion: This study identifies key barriers and facilitators encountered in a middle-income setting. These findings may inform future efforts to implement precision medicine approaches for pediatric cancer in the region.

Aprobación

Revisión

Complementado por

Referenciado por

Licencia Creative Commons

Excepto donde se indique lo contrario, la licencia de este ítem se describe como by-nc-sa